Risk adjusted net present value: What is the current valuation of AstraZeneca’s Puxitatug Samrotecan?
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer.
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer.
What's Your Reaction?
